The Future of Targeted Therapeutics: Key technologies, new therapy area applications

In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and a decline in new drug approvals. Large pharmaceutical companies are coming under pressure to explore new R&D strategies and implement more cost-effective sourcing methods for innovative new molecules.

The biotechnology industry is emerging as a hub of innovation for biomarker and new chemical entity (NCE) identification, and has become a vital component in the preclinical development of new drug technologies. As therapy focus shifts to treating the causal pathway of disease and not merely the symptomology, the majority of emerging targeted therapeutics are large molecule biologics, while monoclonal antibody therapies represents the fastest growing segment within the pharmaceutical industry.

Read more...

• Diagnostics in Neurology (09/10/2008)
• R&D Strategies (20/05/2008)
• Innovations in Bioinformatics (12/05/2008)

• The Future of Biosimilars (14/05/2008)
• Cardiovascular Disease Management (14/05/2008)
• Nanotechnology (12/05/2008)

• Nosocomial Vaccines (12/05/2008)
• HRT for Menopausal Symptoms (12/05/2008)
• CNS Market Overview (12/05/2008)

---